Con: Activated Clotting Time Should Not Be Monitored During Heparinization for Vascular Surgery

Wolo, Elizabeth; Herman, Corey R.

doi:10.1053/j.jvca.2017.05.043

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2007, the co-operation between medical and surgical vascular, cardiovascular, vascular radiology and cardiology societies produced a consensus document on peripheral arterial disease, where ACT monitoring for UFH effect was recommended [ 1 ]. Yet, the utility of ACT measurement is still debated, with viewpoints for and against published recently [ 13 , 14 ]. Universal guidelines on ACT target levels, however, remain a challenge, as different devices are known to differ in their sensitivities to heparin as well as to patient-related confounders (e.g., Hgb, fibrinogen, FVIII levels, other anticoagulants) [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure

et al. 2023

View full text Add to dashboard Cite

Activated clotting time (ACT) is used in cardiac surgery for monitoring unfractionated heparin (UFH). In endovascular radiology, ACT use is less established. We aimed to test the validity of ACT in UFH monitoring in endovascular radiology. We recruited 15 patients undergoing endovascular radiologic procedure. ACT was measured with ICT Hemochron® device as point-of-care (1) before standard UFH bolus, (2) immediately after the bolus, and in some cases (3) 1 h into the procedure or a combination thereof (altogether 32 measurements). A total of two different cuvettes, ACT-LR and ACT+ were tested. A reference method of chromogenic anti-Xa was used. Blood count, APTT, thrombin time and antithrombin activity were also measured. UFH levels (anti-Xa) varied between 0.3–2.1 IU/mL (median 0.8) and correlated with ACT-LR moderately (R2 = 0.73). The corresponding ACT-LR values were 146–337 s (median 214). ACT-LR and ACT+ measurements correlated only modestly with one another at this lower UFH level, with ACT-LR being more sensitive. Thrombin time and APTT were unmeasurably high after the UFH dose, rendering them of limited use in this indication. We adopted an ACT target of >200–250 s in endovascular radiology based on this study. While ACT correlation with anti-Xa is suboptimal, the readily available point-of-care nature increases its suitability.

show abstract